Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ARYx initiates enrollment in Phase II/III anticoagulation trial
The purpose of the trial, named EmbraceAC, is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of
The purpose of the trial, named EmbraceAC, is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of
Most recently, Mr Wulff served as executive vice president and CFO for Artes Medical, a San Diego-based medical technology company. In that position, he assisted the company in
Mr Jacobs has over 30 years of experience in accounting, finance and operations. Since May 2005, he has been CFO and COO of Karat Platinum, which supplies and
In connection with the series A financing, Meritage Pharma announced its founding management team: Cam Garner, chairman; Elaine Phillips, president and CEO; Malcolm Hill, chief scientific officer; and
The company is pursuing patent protection on this unique formulation. Outside the US, the company is moving rapidly to secure regulatory approvals, if needed, in those regions where
The company reported that the best nanoviricide anti-HIV drug candidate improved total hours of survival time by 99% with respect to appropriate controls. In contrast, the combo therapy
These new patents are expected to broaden the company’s intellectual property leadership in the field of targeted anti-aminophospholipid agents. Shelley Fussey, vice president of intellectual property at Peregrine,
The company has engaged Cato Research, a global contract research organization (CRO), as a strategic partner and as the CRO to conduct the Phase III clinical program. The
The companies, which are exploring the possibility of a future marketing collaboration in this area, said the collaboration was discontinued due to current technical incompatibilities between Gen-Probe’s nucleic
Joseph Galli, chairman and CEO of Haemacure, said: “We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into